# Dyadic International, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Dyadic International, Inc). ## Overview Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and nutrition, and bio-industrial applications. It has no approved products for sale today and instead monetizes its C1 and Dapibus platforms through research collaborations, government grants, sublicensing, and related development services. ## Products & services • C1 microbial protein expression platform • Dapibus protein production platform • Research collaboration and development services • Sublicensing and technology transfer arrangements • Government and third-party research programs • Ferritin nanoparticle antigen and vaccine research - **Protein production platforms** (45%) — Core microbial expression systems used to produce commercial quantities of proteins and enzymes. - **Research collaboration services** (35%) — R&D services performed under collaboration agreements and government or commercial projects. - **Sublicensing and technology transfer** (15%) — License-related arrangements, upfront fees, milestones, and potential royalties from platform IP. - **Applied biotech programs** (5%) — Targeted development programs in food, nutrition, life sciences, and bio-industrial markets. - C1 microbial expression platform for industrial and protein production - Dapibus applied biotechnology platform for commercial protein solutions - Research collaboration services under third-party agreements - Sublicensing and technology transfer of platform IP - Government-funded and commercial R&D programs - Ferritin nanoparticle antigen and vaccine candidate research ## Customers Dyadic sells primarily to collaboration partners, licensees, and research sponsors rather than end consumers. Its customer base includes industrial biotechnology companies, life sciences and food/nutrition partners, government or grant-funded programs, and contract research organizations that support its internal and partnered R&D. Revenue is highly concentrated, with a small number of customers accounting for most sales in recent periods. - **Collaboration partners** (primary) — Partners fund research and development work and may pursue future licenses or commercialization rights. - **Licensees and sublicense counterparties** (primary) — Companies that pay for access to Dyadic's platform IP, technology transfer, or milestone-based rights. - **Government and grant-funded sponsors** (secondary) — Public or quasi-public programs that fund research projects and platform development. - **European customers** (secondary) — Non-U.S. customers that buy research services or collaboration access and diversify the revenue base geographically. - **Contract research organizations** (secondary) — CROs are not customers in the usual sense but are critical service providers enabling Dyadic's research execution. - Biotech and industrial partners buying platform access and R&D support - Licensees seeking rights to use C1 or related protein production IP - Government or grant sponsors funding specific research programs - European customers contributing a meaningful share of revenue - CROs supporting outsourced research execution and development work - A few large customers drive most revenue and receivables ## Geography Dyadic is headquartered in Jupiter, Florida and operates in the United States with a satellite office and foreign subsidiary in the Netherlands. Revenue is generated mainly from U.S. and European customers, and the company explicitly discloses meaningful exposure to customers outside the United States. The Netherlands presence matters because it supports international operations and reflects the company’s cross-border research and collaboration model. - **United States** (73.2%) — Derived from 9M 2025 disclosure that European customers were 26.8% of revenue. - **Europe** (26.8%) — Management disclosed European customers accounted for 26.8% of 9M 2025 revenue. - Headquartered in Jupiter, Florida, United States - Operates a foreign subsidiary and satellite office in the Netherlands - Revenue comes from U.S. and European customers - European customers represented 26.8% of 9M 2025 revenue - Cross-border operations increase FX, tax, and compliance complexity ## Strategy Dyadic is shifting from a research-driven organization toward a more commercially focused biotechnology platform under the Dyadic Applied BioSolutions brand. The strategy centers on monetizing its patented C1 and Dapibus platforms through partnerships, sublicensing, and applied programs in food, nutrition, life sciences, and bio-industrial markets. Near term, the company is also focused on preserving liquidity, advancing pre-commercial programs, and securing external funding or strategic collaborations to support development. - **Commercialize the C1 and Dapibus platforms** (medium-term) — The company has no approved products, so platform monetization is the main path to durable revenue. - **Build applied biotech partnerships** (short-term) — Partnerships can fund development, validate the platform, and create downstream licensing opportunities. - **Maintain liquidity and access to capital** (short-term) — The company expects continued operating losses and may need external financing to fund development. - Rebrand toward commercial applied biotechnology solutions - Monetize C1 and Dapibus through partnerships and licensing - Expand into food, nutrition, life sciences, and bio-industrial markets - Advance pre-commercial vaccine and antigen programs - Preserve cash and seek strategic financing if needed ## Risks Dyadic remains a pre-commercial biotechnology company, so its results depend on successful platform validation, partner adoption, and eventual commercialization. Revenue is concentrated in a small number of customers and outsourced research providers, which creates execution and counterparty risk, while the company also faces ongoing funding needs and regulatory uncertainty. As a cross-border biotech platform, it is exposed to IP, compliance, and market-acceptance risks typical of early-stage life sciences businesses. - **Customer concentration** [high] — A small number of customers accounted for most revenue and receivables, so losing one could materially reduce sales and cash flow. - **Dependence on CROs** [high] — Research execution is outsourced to a few contract research organizations, creating operational dependency and potential delays or cost overruns. - **Capital needs and dilution** [high] — The company expects continued operating losses and may need to raise external capital to fund R&D and commercialization. - **Commercialization and regulatory risk** [high] — The platforms must gain market acceptance and, for some programs, regulatory clearance before meaningful product revenue can emerge. - **Intellectual property risk** [medium] — Value depends on protecting proprietary platform technology and license rights from challenge or obsolescence. - No approved products, so revenue depends on collaborations and licensing - Customer concentration makes the loss of one partner material - Heavy reliance on a few CROs creates execution and supply-chain risk - Ongoing losses may require dilutive capital raises - Platform adoption and regulatory acceptance remain uncertain ## Accounting Dyadic’s accounting is dominated by revenue recognition judgments because revenue comes from collaboration services, grants, sublicensing, milestones, and royalties rather than product sales. The company also uses contract assets and deferred revenue when billing timing differs from performance, and its R&D spend is expensed as incurred, which can create volatile quarterly results. Stock-based compensation, investment securities, and potential fair value measurements for noncash consideration can also affect reported earnings and balance sheet values. - **Revenue recognition under ASC 606** — Can shift revenue between quarters and affect comparability - **Contract assets and deferred revenue** — Affects working capital and reported revenue timing - **Research and development expense recognition** — Drives operating loss volatility - **Stock-based compensation** — Can materially affect reported operating costs - **Investment securities and cash equivalents** — Affects liquidity disclosure and interest income - Revenue is recognized over time or at a point in time under collaboration contracts - Upfront fees and timing differences create contract assets and deferred revenue - No approved products means revenue mix can shift sharply by quarter - R&D is expensed as incurred, increasing operating loss volatility - Stock-based compensation and convertible notes affect net loss and equity --- *Last updated: 2026-04-28T20:01:13.479238+00:00*